Loading...
OTCM
RBSH
Market cap3kUSD
Jul 11, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-100.00%
IPO
-100.00%
Name

Rebus Holdings Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
1,005.17%
Rev. gr., 5y
%
Revenues
0k
Net income
-1m
L
-691,199-3,326,261-5,132,827-4,257,839-5,714,107-6,920,000-5,302,000-6,994,000-5,886,000-3,555,000-11,100,000-12,000-1,711,000-4,628,0001,615,000-1,253,000
CFO
-706k
L+1.88%
-78,028-2,649,977-2,010,483-2,769,217-3,744,055-4,521,000-4,707,000-5,044,000-4,633,000-2,733,000-1,092,000-204,000-313,000-374,000-693,000-706,000

Profile

Rebus Holdings, Inc. focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. The company was founded in 2003 and is based in Westlake Village, California.
IPO date
Nov 02, 2009
Employees
1
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
664
Unusual Expense (Income)
NOPBT
(664)
NOPBT Margin
Operating Taxes
233
Tax Rate
NOPAT
(897)
Net income
(1,253)
-177.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
310
Long-term debt
Deferred revenue
Other long-term liabilities
2,284
Net debt
305
Cash flow
Cash from operating activities
(706)
CAPEX
Cash from investing activities
Cash from financing activities
FCF
(478)
Balance
Cash
5
Long term investments
Excess cash
5
Stockholders' equity
(65,294)
Invested Capital
60,367
ROIC
ROCE
13.48%
EV
Common stock shares outstanding
31,819
Price
0.01
-71.80%
Market cap
239
-57.55%
EV
544
EBITDA
(610)
EV/EBITDA
Interest
69
Interest/NOPBT